REMIBRUTINIB SHOWED SUSTAINED EFFICACY AND FAVORABLE SAFETY PROFILE THROUGH WEEK 52 IN CHRONIC INDUCIBLE URTICARIA

Annals of Allergy, Asthma & Immunology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles